Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.69 |
| ▸ | FLT3 | P36888 | 20/20 | 0.69 |
| ▸ | CDK2 | P24941 | 16/20 | 0.69 |
| ▸ | TYK2 | P29597 | 14/20 | 0.69 |
| ▸ | JAK1 | P23458 | 14/20 | 0.69 |
| ▸ | JAK3 | P52333 | 11/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.69 |
| ▸ | CCNA1 | P78396 | 11/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14531001 | 0.93 | JAK2 (0.67) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL1108235 | 0.93 | JAK2 (0.79) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL824033 | 0.90 | JAK2 (0.68) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL824117 | 0.86 | FLT3 (0.68) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL1108243 | 0.86 | JAK2 (0.74) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL823861 | 0.85 | JAK2 (0.79) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL1108238 | 0.83 | JAK2 (0.70) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL1108234 | 0.83 | JAK2 (0.70) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL1108222 | 0.82 | JAK2 (1.00) | JAK2FLT3CDK2TYK2JAK1 | |
| SCHEMBL823917 | 0.81 | FLT3 (0.75) | JAK2FLT3CDK2TYK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-9133214-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD (SG) | 2015-09-15 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-06-07 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143255-B2 | Heteroalkyl linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| EP-1951730-B1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S BIO PTE LTD (SG) | 2010-05-26 | — | — | EP | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| WO-2007058628-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | JAK2 692/4885FLT3 424/4885CDK2 13/4885 |
| US-20120142680-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | JAK2 692/4885FLT3 424/4885CDK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.